Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Beijing Tiantan Biological Products Co., Ltd.
  6. Summary
    600161   CNE000000WF9

BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.

(600161)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
10/20/2021 10/21/2021 10/22/2021 10/25/2021 10/26/2021 Date
32.73 32.13 32.32 30.95 30.74 Last
5274547 8533799 8281700 20139430 9876859 Volume
+0.65% -1.83% +0.59% -4.24% -0.68% Change
Estimated financial data (e)
Sales 2021 3 988 M 625 M 625 M
Net income 2021 773 M 121 M 121 M
Net Debt 2021 - - -
P/E ratio 2021 54,7x
Yield 2021 0,47%
Sales 2022 4 679 M 733 M 733 M
Net income 2022 957 M 150 M 150 M
Net Debt 2022 - - -
P/E ratio 2022 44,0x
Yield 2022 0,57%
Capitalization 42 211 M 6 613 M 6 614 M
Capi. / Sales 2021 10,6x
Capi. / Sales 2022 9,02x
Nbr of Employees 3 592
Free-Float 42,6%
More Financials
Company
BEIJING TIANTAN BIOLOGICAL PRODUCTS CORPORATION LIMITED is a China-based company principally engaged in the biopharmaceutical businesses. The CompanyÔÇÖs primary products include preventive products, blood products and other biological products, such as the influenza A (H1N1) vaccines (split, inactivated),hepatitis B vaccines, poliomyelitis vaccines, measles-mump-rubella (MMR) vaccines, encephalitis B vaccines,... 
Sector
Pharmaceuticals
Calendar
10/28Earnings Release
More about the company
Ratings of Beijing Tiantan Biological Products Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.
07/14Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Half Yea..
CI
04/29BEIJING TIANTAN BIOLOGICAL PRODUCTS : Indonesia approves Sinopharm COVID-19 vaccine for em..
RE
04/26Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the First Qu..
CI
04/16EXCLUSIVE : Sinopharm to inject $4.6 billion vaccine assets into unit Tiantan Biological -..
RE
04/16Sinopharm plans to inject $4.6 bln in assets into unit beijing tiantan biological produ..
RE
2020BEIJING TIANTAN BIOLOGICAL PRODUCTS : 600161) added to Shanghai Stock Exchange 180 Value ..
CI
2020BEIJING TIANTAN BIOLOGICAL PRODUCTS : 600161) added to SSE 180 Index
CI
2020Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Nine Mon..
CI
2020Chengdu Rongsheng Pharmaceutical Co., Ltd. announced that it expects to receive CNY 2.5..
CI
2020Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Half Yea..
CI
2020Beijing Tiantan Biological Products Co., Ltd. Announces Cash Dividend for the Year 2019..
CI
2020Jianli Wu Xin Apheresis Station Co., Ltd. announced that it expects to receive CNY 25 ..
CI
2020Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the First Qu..
CI
2020Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Full Yea..
CI
2020Beijing Tiantan Biological Products Co., Ltd. Provides Financial Guidance for 2019
CI
More news
News in other languages on BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.

- No features available -

More news
Chart BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Beijing Tiantan Biological Products Co., Ltd. Technical Analysis Chart | 600161 | CNE000000WF9 | MarketScreener
Technical analysis trends BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 30,74 CNY
Average target price 38,40 CNY
Spread / Average Target 24,9%
EPS Revisions
Managers and Directors
Dao Xing Fu General Manager & Director
Yi Zhang Chief Financial Officer & Deputy General Manager
Xiao Ming Yang Chairman
Jing Jin Zhu Chairman-Supervisory Board
Hong Guang Wang Independent Director
Sector and Competitors